Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model
- Alexia Kieffer; Matthieu Beuvelet; Aditya Sardesai; Robert Musci; Sandra Milev; Julie Roiz
Access Resources
About
This article describes a study on the impact of using nirsevimab for all infants in the U.S. during their first RSV season. It looks at how this immunization could affect health outcomes and costs related to RSV, a common respiratory virus in babies. The study uses a static model to predict these effects. The article is available on official government websites, ensuring secure access to information about this important research on infant health and disease prevention strategies against RSV-related issues and expenses.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.